Men and women may be affected differently by retinitis pigmentosa, a disease that causes blindness over time. That's ...

Aldeyra Therapeutics received FDA fast track designation for ADX-2191 for the treatment of retinitis pigmentosa, according to ...

Retinitis pigmentosa (RP) is a term for a group of eye diseases that can lead to loss of sight. What they have in common are specific changes your doctor sees when they look at your retina – a ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal ...

ADX-2191 is a preservative-free intravitreal formulation of methotrexate designed to treat various rare retinal diseases such as retinitis pigmentosa.

Treatment With 9-cis Beta-Carotene-Rich Powder in Patients With Retinitis Pigmentosa: A Randomized Crossover Trial Rotenstreich Y, Belkin M, Sadetzki S, et al. JAMA Ophthalmol. 2013;131:985-992.

This work can be read in the journal PLOS Biology. Retinitis pigmentosa is the most common hereditary retinal disease in humans, with a prevalence of one in every 4,000 people worldwide.

Retinitis pigmentosa is an eye disease in which there is damage to the retina. Approximately 2 million individuals (about 1 in 4,000) worldwide are affected by the condition, which typically ...

In this Healio Video Perspective from the Retina World Congress, Huma Qamar, MD, MPH, of Ocugen, overviews programs for ...

Other causes of retinitis pigmentosa Non-inherited or non-genetic causes of retinitis pigmentosa are rare. This means that it is rare to find a case where there is no family history of the condition.

Retinitis Pigmentosa Market Dublin, June 26, 2025 (GLOBE NEWSWIRE) -- The "Retinitis Pigmentosa Market Opportunities and Strategies to 2034" report has been added to ResearchAndMarkets.com's offering.